Next Phase Newsletter

A global biopharmaceutical company with offices in the US and Europe is looking to in-license technology of interest and also makes select equity investments. The investment size is highly variable and has ranged from $1 million to $10s of millions. The firm invests in companies so the candidate technology can improve the lives of patients, not to make financial returns. The group does not have a goal for the number of deals this year. The firm made over 10 deals in the past year, and a few of these were equity investments. The group considers partnerships and investments globally.

The firm is interested in therapeutic biotechnology. The group is platform agnostic and will consider small molecules, biologics, or cell and gene therapy. Primary indications of interest include oncology, hematology, inflammation, and immunology. The firm will consider orphan indications but is less interested in ultra-orphan indications. The firm will consider companies across all phases of development, with a slight preference for later stage companies.

The firm prefers companies with experienced management teams and often seeks a board observer seat. Technologies of interest are generally not yet profitable. For equity deals, the firm does not want to be the first investor and prefers opportunities that have previous VC involvement. The group prefers to syndicate with other investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global alternative asset manager based in China focuses on investments in the healthcare sector, providing equity and/or mezzanine capital to early and growth-stage companies. The firm has raised four funds to date and is making new investments from its fourth 2014 vintage fund. Depending on the stage of the company, the firm can invest from several hundred thousand to tens of millions. The firm is geographically agonistic and looks to invest in companies based in the US, Europe, Israel, and Asia. The firm is actively seeking new investment opportunities.       

In the Life Sciences the firm is currently seeking to invest in medical devices. The firm primarily invests in novel and disruptive technologies. The firm is opportunistic in terms of the class/type and development stage of the device. Hence, the firm will consider devices at all stages: prototype, in clinic, to commercial stage. The firm is currently looking for opportunities in the hypertension, oncology, and diabetes market. Currently the firm is only looking for privately held companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

 A Venture Capital company with offices in the US and Europe is currently looking to make investments out of its fourth fund. The firm is looking to make venture stage investment generally falling in the range of $2-$6 million though investments may fall outside of this range depending upon the opportunity. The firm also reserves additional capital for follow on rounds. The firm is most interested in companies based in the US although they are also open to investing in Eastern and Northern Europe, East Asia and Australia. The firm could make as many as 5-10 investments over the next year.

The firm is primarily interested in companies developing therapeutics and to a lesser extent medical devices and research tools. Within the Therapeutics space the firm has a slight preference for companies working with platform technologies although they are open to single asset companies as well. The firm is willing to invest in small molecules, biologics, and cell and gene therapy. The firm is willing to consider opportunities from preclinical through phase III of clinical trials though most of their investments will likely be allocated to later stage companies. The firm generally only considers pre-clinical stage companies if there is a clear path to exit in a shortened timeframe. The firm is highly interested in area of RNA therapeutics, Oncology, Structural Heart and Gene Therapy and is generally less interested in CNS disorders.  For medical device companies the firms looks for technologies that are into clinical trials with a working prototype and is agnostic in terms of technology type and indication.

The firm is looking for private or publically held companies, and has special interest in companies considering going public as well as secondary’s investments. The firm prefers to invest as a member of a syndicate and does not always require a board seat following investment. The firm looks to act as a value add investor helping companies expand their networks and filling in holes in existing management.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The operational and investment arm of a family office is looking to make equity investments into early stage companies and small mid-market growth companies ranging from $.5 to $1 million. The firm is very open to syndication particular with early stage deals and is capable of providing additional capital in follow on rounds when appropriate. The firm prefers to invest in companies located in the eastern United States and looks to make approximately 1-2 new investments per year.

The firm is looking for companies in the Medical Technology and Diagnostics space. Within these areas the firm is looking for 510k devices that are more technically based with a particular interest in hospital equipment and professional diagnostics. The firm is not interested in devices where the final consumer is the patient. The firm is looking to devices that improve the standard of care and is willing to invest in companies at all phases of development. The firm is generally open to all indications.

The firm looks for experienced management teams and looks to take a board seat following investment. The firm is willing to work with companies that have incomplete management teams and is looking for privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com